Conference Cochairs:
Ravi Majeti, Stanford University, Stanford, CA
Maria (Ken) Figueroa, University of Miami, Miami, FL
Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

[R] – remote presentation

* - short-talk from proffered abstract

MONDAY, JANUARY 23

Registration
3:00 pm-8:00 pm | Zilker Ballroom Foyer

Welcome and Keynote Lectures
5:00 pm-6:30 pm | Zilker Ballroom 1

5:00-5:05  Welcome and Introduction of Keynote Speaker
Ravi Majeti, Stanford University, Stanford, CA

5:05-5:35  Understanding and targeting altered RNA splicing in myeloid malignancies
Omar Abdel-Wahab, Memorial Sloan Kettering Cancer Center, New York, NY

5:35-5:45  Discussion / Q&A

5:45-6:20  Introduction of Keynote Speaker
Maria (Ken) Figueroa, University of Miami, Miami, FL

5:50-6:20  Germline predisposition to myeloid malignancies
Lucy A. Godley, University of Chicago, Chicago, IL

6:20-6:30  Discussion / Q&A

Opening Reception
6:45 pm-8:30 pm | Zilker Ballroom Foyer and Terrace

TUESDAY, JANUARY 24

Continental Breakfast
7:00 am-8:00 am | Zilker Ballroom 2
Plenary Session 1: Apoptosis  
8:00 am-9:35 am | Zilker Ballroom 1  
Session Chair: Courtney D. DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00-8:05  Introduction  
Courtney D. DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX

8:05-8:25  Inducing apoptosis in leukemia stem cells by targeting metabolism  
Courtney L. Jones, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

8:25-8:30  Discussion / Q&A

8:30-8:50  Understanding and preventing resistance to BCL2 inhibitor therapy in AML  
Courtney D. DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX

8:50-8:55  Discussion / Q&A

8:55-9:15  Understanding differential addiction to anti-apoptotic BCL-2 family towards developing novel treatments in hematological malignancies  
Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, MI

9:15-9:20  Discussion / Q&A

9:20-9:35  Panel Discussion

Break  
9:35 am-9:55 am | Zilker Ballroom Foyer

Plenary Session 2: Stem Cells  
9:55 am-11:45 am | Zilker Ballroom 1  
Session Chair: Ravi Majeti, Stanford University, Stanford, CA

9:55-10:00  Introduction  
Ravi Majeti, Stanford University, Stanford, CA

10:00-10:20  Approaches to targeting leukemia stem cells  
Monica L. Guzman, Weill Cornell Medicine, New York, NY

10:20-10:25  Discussion / Q&A

10:25-10:45  Mapping the cellular origins of pediatric leukemia  
Eric R. Lechman, University of Pittsburgh, Pittsburgh, PA

10:45-10:50  Discussion / Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50-11:10</td>
<td>Stem cells in human AML</td>
</tr>
<tr>
<td></td>
<td>Ravi Majeti, Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>11:10-11:15</td>
<td>Discussion / Q&amp;A</td>
</tr>
<tr>
<td>11:15-11:25</td>
<td>Novel anti-leukemia activity of the IRE1-XBP1 signaling pathway in</td>
</tr>
<tr>
<td></td>
<td>hematopoietic stem and progenitor cells *</td>
</tr>
<tr>
<td></td>
<td>Stanley Adoro, National Cancer Institute, Bethesda, MD</td>
</tr>
<tr>
<td>11:25-11:30</td>
<td>Discussion / Q&amp;A</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>11:45 am-12:00 pm</td>
<td>Zilker Ballroom Foyer</td>
</tr>
</tbody>
</table>

**Plenary Session 3: Epigenetics**

12:00 pm-1:30 pm | Zilker Ballroom 1

*Session Chair: Maria (Ken) Figueroa, University of Miami, Miami, FL*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:05</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>Maria (Ken) Figueroa, University of Miami, Miami, FL</td>
</tr>
<tr>
<td>12:05-12:20</td>
<td>Epigenomic landscapes of MDS</td>
</tr>
<tr>
<td></td>
<td>Maria (Ken) Figueroa, University of Miami, Miami, FL</td>
</tr>
<tr>
<td>12:20-12:25</td>
<td>Discussion / Q&amp;A</td>
</tr>
<tr>
<td>12:25-12:45</td>
<td>Enhancing TET function for the treatment of myeloid malignancies</td>
</tr>
<tr>
<td></td>
<td>Luisa Cimmino, University of Miami Miller School of Medicine, Miami, FL</td>
</tr>
<tr>
<td>12:45-12:50</td>
<td>Discussion / Q&amp;A</td>
</tr>
<tr>
<td>12:50-1:10</td>
<td>Targeting IDH-mutant myeloid malignancies by disabling metabolic</td>
</tr>
<tr>
<td></td>
<td>dependencies</td>
</tr>
<tr>
<td></td>
<td>Jian Xu, UT Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>1:10-1:15</td>
<td>Discussion / Q&amp;A</td>
</tr>
<tr>
<td>1:15-1:30</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

**Lunch on own / Free time**

1:30 pm-3:15 pm
### Plenary Session 4: Niche/Microenvironment

3:15 pm-5:15 pm | Zilker Ballroom 1  
*Session Chair: Iannis Aifantis, NYU Langone Medical Center, New York, NY*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 3:15-3:20 | Introduction  
Iannis Aifantis, NYU Langone Medical Center, New York, NY |
| 3:20-3:40 | [R] - Dissecting the cross-talk between normal, leukemic stem cells, and the bone marrow microenvironment  
Dominique Bonnet, The Francis Crick Institute, London, England |
| 3:40-3:45 | Discussion / Q&A |
| 3:45-4:05 | [R] - MSCs boost AML bioenergetics and facilitate escape from chemotherapy  
Simón Méndez-Ferrer, University of Cambridge, Cambridge, England |
| 4:05-4:10 | Discussion / Q&A |
| 4:10-4:30 | Anatomy of normal and leukemic hematopoiesis in the bone marrow  
Daniel Lucas, Cincinnati Children's Hospital Medical Center, Cincinnati, OH |
| 4:30-4:35 | Discussion / Q&A |
| 4:35-4:55 | Interactions with the immune microenvironment in MDS and AML  
Iannis Aifantis, NYU Langone Medical Center, New York, NY |
| 4:55-5:00 | Discussion / Q&A |
| 5:00-5:15 | Panel Discussion |

**Break**  
5:15 pm-5:30 pm | Zilker Ballroom Foyer

### Plenary Session 5: Splicing Mutations

5:30 pm-7:05 pm | Zilker Ballroom 1  
*Session Chair: Esther A. Obeng, St. Jude Children’s Research Hospital, Memphis, TN*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 5:30-5:35 | Introduction  
Esther A. Obeng, St. Jude Children’s Research Hospital, Memphis, TN |
| 5:35-5:55 | Targeting the Rbm39 splicing factor in myeloid leukemias and bone marrow transplantation  
Sydney X. Lu, Stanford University School of Medicine, Palo Alto, CA |
| 5:55-6:00 | Discussion / Q&A |
6:00-6:20  Targeting SF3B1 in myelodysplastic syndromes  
Esther A. Obeng, St. Jude Children’s Research Hospital, Memphis, TN
6:20-6:25  Discussion / Q&A

6:25-6:45  Genetic determinants of clonal expansion rate in pre-malignant HSCs  
Siddhartha Jaiswal, Stanford University, Stanford, CA
6:45-6:50  Discussion / Q&A

6:50-7:05  Panel Discussion

Poster Session / Reception  
7:15 pm-9:30 pm | Zilker Ballroom 3

WEDNESDAY, JANUARY 25

Continental Breakfast  
7:00 am-8:00 am | Zilker Ballroom 2

Plenary Session 6: Measurable Residual Disease  
8:00 am-9:35 am | Zilker Ballroom 1  
Session Chair: Christopher S. Hourigan, National Heart, Lung and Blood Institute, Bethesda, MD

8:00-8:05  Introduction  
Christopher S. Hourigan, National Heart, Lung and Blood Institute, Bethesda, MD

8:05-8:25  Measurable residual disease in AML: A roadmap for evidence and implementation  
Christopher S. Hourigan, National Heart, Lung and Blood Institute, Bethesda, MD
8:25-8:30  Discussion / Q&A

8:30-8:50  Measurable residual disease assessment for lower intensity therapy in AML  
Farhad Ravandi-Kashani, The University of Texas MD Anderson Cancer Center, Houston, TX
8:50-8:55  Discussion / Q&A

8:55-9:15  Targeting senescence-like resilient AML cells to reduce measurable/minimal residual disease  
Cihangir Duy, Fox Chase Cancer Center, Philadelphia, PA
9:15-9:20  Discussion / Q&A

9:20-9:35  Panel Discussion
Break
9:35 am-9:55 am | Zilker Ballroom Foyer

Plenary Session 7: Inflammation
9:55 am-11:45 am | Zilker Ballroom 1
Session Chair: Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

9:55-10:00  Introduction
Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

10:00-10:20  Inflammation and the MPNs: From phenotype to therapy
Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
10:20-10:25  Discussion / Q&A

10:25-10:45  Age- and gut injury-induced accumulation of a bacterial metabolite promotes expansion of leukemic cells
Daniel T. Starczynowski, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
10:45-10:50  Discussion / Q&A

10:50-11:10  Fish and CHIPs: Dissecting the mechanisms of clonal disorders using cellular barcoding
Serine Avagyan, University of California, San Francisco, CA
11:10-11:15  Discussion / Q&A

11:15-11:25  RSK1 targeting impedes oncogenic driver and inflammatory cytokine signaling to attenuate myeloid neoplasms *
Tim Kong, Washington University in St. Louis School of Medicine, St. Louis, MO
11:25-11:30  Discussion / Q&A

11:30-11:45  Panel Discussion

Break
11:45 am-12:00 pm | Zilker Ballroom Foyer
Plenary Session 8: Cell and Immune Targeting in Myeloid Malignancies
12:00 pm-1:25 pm | Zilker Ballroom 1
Session Chair: Paresh Vyas, University of Oxford, Oxford, United Kingdom

12:00-12:05  Introduction
Paresh Vyas, University of Oxford, Oxford, United Kingdom

12:05-12:25  Graft versus Leukemia (GvL): Identification and characterization of alloreactive antigens and cognate T cell responses in acute myeloid leukemia
Paresh Vyas, University of Oxford, Oxford, United Kingdom
12:25-12:30  Discussion / Q&A

12:30-12:50  Bispecific split CD13/TIM3 CAR T cells eliminate AML in vivo without toxicity in preclinical models
Xianxin Hua, Abramson Family Cancer Research Institute University of Pennsylvania, Philadelphia, PA
12:50-12:55  Discussion / Q&A

12:55-1:05  ADCLEC.syn1 CAR T cells detect combinatorial target signatures to safely prevent antigen-low AML escape *
Sascha Haubner, Memorial Sloan Kettering Cancer Center, New York, NY
1:05-1:10  Discussion / Q&A

1:10-1:25  Panel Discussion

Closing Remarks and Departure
1:25 pm-1:30 pm | Zilker Ballroom 1
Ruben A. Mesa, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC